Joerg Windisch, PhD Sandoz International GmbH

Joerg Windisch has been working on the development of both, innovative and follow-on biologics for his entire professional career. He joined Sandoz in 1996 as a day one member of the company's biosimilars program and played leading roles in the development of Sandoz' Somatropin product (Omnitrope®), the first ever biosimilar medicine, as well as of the company's Epoetin alfa (Binocrit®) and Filgrastim (Zarzio®) products. Over 15 years, he built up an international technical development organization for biosimilars comprising several hundred experts. For the last 6 years, he has been focusing on the development of biosimilar monoclonal antibodies. Dr. Windisch is also the Chair of the European Generic medicines Association's (EGA's) European Biosimilars Group (EBG). The EBG represents the biosimilars industry in Europe. He has published extensively on biosimilars and biologics and holds numerous patents in the field. Dr. Windisch holds a Ph.D. in biochemistry.